Drug WatchNew Drug to Reduce the Risk of Preterm BirthAschenbrenner, Diane S. MS, RNAuthor Information Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: [email protected]. AJN, American Journal of Nursing: June 2011 - Volume 111 - Issue 6 - p 24-25 doi: 10.1097/01.NAJ.0000398535.21789.c1 Buy Metrics Abstract Hydroxyprogesterone caproate (Makena) is the first drug approved to prevent preterm labor. Hydroxyprogesterone caproate is given weekly by injection to women who've had at least one premature birth. It's intended for use only in singleton pregnancies. Injection-site reactions are the most common adverse effect; others are hives, nausea, and diarrhea. © 2011 Lippincott Williams & Wilkins, Inc.